Skip to content

Advertisement

  • Letter
  • Open Access

Serum IL-33 level is associated with auto-antibodies but not with clinical response to biologic agents in rheumatoid arthritis

  • 1,
  • 2,
  • 1,
  • 3,
  • 4 and
  • 1, 5Email author
Contributed equally
Arthritis Research & Therapy201820:122

https://doi.org/10.1186/s13075-018-1628-6

  • Published:

Trial registration

Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (ROC), registered 22 October 2009, NCT01000441

Keywords

  • Interleukin 33
  • Personalized medicine
  • Rheumatoid arthritis
  • Biologic agents

Interleukin (IL)-33 may play a role in rheumatoid arthritis (RA) pathophysiology as shown by human studies and murine models [1]. Previously, we demonstrated that detectable serum IL-33 predicts clinical response to rituximab independently of auto-antibody status [2].

Here, we aimed to investigate whether the prediction of therapeutic response using serum IL-33 level is generalizable to all biologic agents, including TNF inhibitors (TNFi) and non-TNFi in RA.

We set up an ancillary study of the ROC (Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for RA) trial (NCT01000441) which compared the efficacy of TNFi vs non-TNFi in patients with insufficient response to a first TNFi [3]. Three hundred patients were randomized, and treatment efficacy was evaluated at 24 weeks according to EULAR response, showing that a non-TNFi was more effective in achieving EULAR response than a TNFi. Serum IL-33 level was assessed before treatment using an accurate enzyme-linked immunosorbent assay (ELISA IL-33, Quantikine, R&D Systems) [4]. Statistical analyses used Prism (Mann-Whitney and Fisher tests for quantitative and qualitative values, respectively). Serum IL-33 level was defined as detectable when > 6.25 pg/mL (lower threshold).

Results were analyzed for 267 patients with available serum and clinical data (Table 1). Serum IL-33 level was detectable for 109/267 (40.8%) patients (mean ± standard deviation serum level was 49.7 ± 61.0 pg/mL when detectable) (Table 2). IL-33 detection was associated with auto-antibody positivity: rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP), either combined or analyzed separately (Table 3). Auto-antibody positivity was not associated with response to the different treatment: TNFi (N = 132, odds ratio (OR) = 1.1, 95% confidence interval (CI) = 0.39–3.16), non-TNFi (N = 130, OR = 1.5, 95% CI = 0.40–5.62), or different sub-groups of non-TNFi (data not shown). There was no association between IL-33 detection and response to TNFi as well as to non-TNFi drugs overall or analyzed separately (Table 2). Likewise, there was no difference when comparing the levels of serum IL-33 between responders and non-responders in TNFi and non-TNFi groups (data not shown).
Table 1

Characteristics of the patients included in the ancillary study of the ROC trial

Characteristics

TNFi

Non-TNFi biologic

Total

Number of women (%)

114 (85.7)

110 (82.1)

224 (83.9)

Mean age (SD)

55.9 (13.0)

58.4 (11.2)

57.2 (12.1)

Number rheumatoid factor-positive (%)

108 (82.4)

101 (76.5)

209 (79.8)

Number anti-CCP-positive (%)

102 (79.7)

105 (82.7)

207 (81.2)

Mean DAS28-CRP (SD)

4.7 (0.9)

4.8 (1.1)

4.8 (1.0)

Table 2

EULAR response, IL-33 detectability rates and association between IL-33 detection and response to tumor necrosis factor inhibitor (TNFi; including adalimumab, certolizumab, etanercept and infliximab) and non-TNFi (including abatacept, rituximab, and tocilizumab) in patients from the ROC study

 

Treatment

Number of patients

Number of EULAR responders (%)

Number of detectable IL-33 among all patients (%)

Number of detectable IL-33 among EULAR responders (%)

Association between IL-33 detectability and EULAR response (OR [95% CI])

TNFi

Adalimumab

53

30 (56.6)

23 (43.4)

14 (46.7)

1.4 [0.5–4.1]

Etanercept

49

29 (59.2)

20 (40.8)

13 (44.8)

1.5 [0.5–5.0]

Certolizumab

23

10 (43.5)

10 (43.5)

5 (50.0)

1.6 [0.3–8.5]

Infliximab

8

1 (12.5)

3 (37.5)

1 (100)

6.6 [0.2–226]

Total TNFi

133

70 (52.6)

56 (42.1)

33 (47.1)

1.6 [0.8–3.1]

Non-TNFi

Rituximab

37

20 (54.0)

10 (27.0)

6 (30.0)

1.4 [0.3–6.1]

Abatacept

30

18 (60.0)

11 (36.6)

8 (44.4)

2.4 [0.5–11.9]

Tocilizumab

67

53 (79.1)

32 (47.8)

25 (47.2)

0.9 [0.3–2.9]

Total non-TNFi

134

91 (67.9)

53 (39.6)

39 (42.9)

1.6 [0.7–3.3]

Results are presented as odds ratios (OR) [95% confidence intervals (CI)]

Table 3

Association between IL-33 detection and auto-antibody positivity

Auto-antibody status

Number of patients

OR

95% CI

RF+ and/or anti-CCP+ vs RF− and anti-CCP−

262

21.1

2.8-158.3

RF+ vs RF−

263

9.7

3.7-25.3

Anti-CCP+ vs anti-CCP−

255

2.7

1.3- 5.7

Results are presented as odds ratios (OR), 95% confidence intervals (CI) for each factor

RF rheumatoid factor, Anti-CCP anti-cyclic citrullinated peptide antibody

Thus, this new study confirms the association between serum IL-33 detection and seropositivity in RA patients. However, it did not replicate the association between IL-33 detection and response to rituximab. This may be due to a lack of power related to the number of patients who received this treatment (N = 37), but it may also reflect the difficulty of studying IL-33 as a possible predictor of response given its association with seropositivity, which is a well-known factor associated with response to some biologics such as rituximab or abatacept [5].

In conclusion, we confirm that serum IL-33 detection is associated with auto-antibody positivity but is not a predictive marker for response to TNFi and non-TNFi in RA.

Notes

Abbreviations

Anti-CCP: 

Anti-cyclic citrullinated peptide

CI: 

Confidence interval

ELISA: 

Enzyme-linked immunosorbent assay

EULAR: 

European League Against Rheumatism

Ig: 

Immunoglobulin

IL: 

Interleukin

OR: 

Odds ratio

RA: 

Rheumatoid arthritis

RF: 

Rheumatoid factor

TNFi: 

Tumor necrosis factor inhibitor

Declarations

Acknowledgements

The authors thank all patients for participating in this study and all investigators who included patients in the ROC study : Olivier Brocq, MD; Aleth Perdriger, MD; Slim Lassoued, MD; Jean-Marie Berthelot, MD; Daniel Wendling, MD, PhD; Liana Euller-Ziegler, MD; Martin Soubrier, MD; Christophe Richez, MD, PhD; Bruno Fautrel, MD, PhD; Arnaud L. Constantin, MD, PhD; Jacques Morel, MD, PhD; Melanie Gilson, MD; Gregoire Cormier, MD; Jean Hugues Salmon, MD; Stephanie Rist, MD; Frederic Lioté, MD, PhD; Hubert Marotte, MD, PhD; Christine Bonnet, MD; Christian Marcelli, MD, PhD; Olivier Meyer, MD, PhD; Elisabeth Solau-Gervais, MD, PhD; Sandrine Guis, MD, PhD; Jean-Marc Ziza, MD; Charles Zarnitsky, MD; Isabelle Chary-Valckenaere, MD, PhD; Olivier Vittecoq, MD, PhD; Alain Saraux, MD, PhD; Yves-Marie Pers, MD, PhD; Martine Gayraud, MD; Gilles Bolla, MD; Pascal Claudepierre, MD, PhD; Marc Ardizzone, MD; Emmanuelle Dernis, MD; Maxime A. Breban, MD, PhD; Olivier Fain, MD, PhD; Jean-Charles Balblanc, MD; Ouafaa Aberkane, PhD; Marion Vazel, PhD; Christelle Back, PhD; Sophie Candon, MD, PhD; Lucienne Chatenoud, MD, PhD; Elodie Perrodeau, MSc; Jean Sibilia, MD  

Funding

The main ROC study was sponsored by the French Ministry of Health (Programme Hospitalier de Recherche Clinique National 2009/4507 EUDRACT No: 2009-013482-26) and promoted by The Direction de la Recherche Clinique et de l’Innovation, Strasbourg University Hospital. The funding agency had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; the decision to submit for publication or preparation, review, or approval of the manuscript for publication.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

ER participated in conception and design of the study, performed acquisition of the data, performed the statistical analysis and interpretation of the results, and wrote the manuscript. JS participated in conception and design of the study, participated in the statistical analysis and interpretation of the results, and wrote the manuscript. JP participated in the design of the study and the acquisition of the data. PR participated in interpretation of the data. JEG is the principal investigator of the main ROC. He participated in the conception and design of the study and in interpretation of the data. XM participated in conception and design of the study, statistical analysis and interpretation of the results, and wrote the manuscript. All authors reviewed and approved the final manuscript.

Ethics approval and consent to participate

The trial (Clinicaltrials.gov identifier NCT01000441) was approved by the institutional review board of the Comité de Protection des Personnes-Est 1, Strasbourg, France. The study was conducted according to the current regulations of the International Conference on Harmonization guidelines and the principles of the Declaration of Helsinki. All patients gave written informed consent after receiving oral and written information about the trial.

Consent for publication

We confirm that all authors approved the manuscript for submission.

Competing interests

Dr. Rivière reported receiving a PhD grant from Fondation Arhtirits Courtin.

Dr. Sellam reported receiving grant support from Roche, Bristol-Myers Squibb, and Pfizer and personal fees from Roche, Pfizer, Abbvie, Bristol-Myers Squibb, Merck Sharp and Dohme, UCB, Janssen, Sandoz, and Novartis.

Dr. Gottenberg reported receiving grant support from Abbvie, Pfizer, and Roche and personal fees from Bristol-Myers Squibb, Merck, Sharp, and Dohme, UCB, GlaxoSmithKline, and Novartis.

Dr. Mariette reported receiving personal fees from Pfizer, UCB, Bristol-Myers Squibb, and GlaxoSmithKline and grant support from Roche, Pfizer, Bristol-Myers Squibb, GlaxoSmithKline, and Biogen.

No other disclosures were reported.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Immunology of viral Infections and Autoimmune Diseases, IDMIT, CEA - Université Paris Sud - INSERM UMR1184, Le Kremlin Bicêtre & Fontenay aux Roses, France
(2)
Department of Rheumatology, Saint-Antoine Hospital, Université Paris 6, INSERM UMRS 938, DHU i2B, Paris, France
(3)
Department of Epidemiology and Biostatistics, Hotel Dieu, Paris, France
(4)
Department of Rheumatology, National Reference Center for Systemic Autoimmune Diseases, Strasbourg University Hospital, Université de Strasbourg, Strasbourg, France
(5)
Department of Rheumatology, Université Paris Sud, 63 rue Gabriel Péri, 94270 Le Kremlin Bicetre, France

References

  1. Sellam J, Marion-Thore S, Dumont F, Jacques S, Garchon H-J, Rouanet S, et al. Use of whole-blood transcriptomic profiling to highlight several pathophysiologic pathways associated with response to rituximab in patients with rheumatoid arthritis: data from a randomized, controlled, open-label trial. Arthritis Rheumatol. 2014;66(8):2015–25.View ArticlePubMedGoogle Scholar
  2. Sellam J, Rivière E, Courties A, Rouzaire P-O, Tolusso B, Vital EM, et al. Serum IL-33, a new marker predicting response to rituximab in rheumatoid arthritis. Arthritis Res Ther. 2016;18(1):294.View ArticlePubMedPubMed CentralGoogle Scholar
  3. Gottenberg J-E, Brocq O, Perdriger A, Lassoued S, Berthelot J-M, Wendling D, et al. Non-TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial. JAMA. 2016;316(11):1172–80.View ArticlePubMedGoogle Scholar
  4. Rivière E, Ly B, Boudaoud S, Chavez H, Nocturne G, Chanson P, et al. Pitfalls for detecting interleukin-33 by ELISA in the serum of patients with primary Sjögren syndrome: comparison of different kits. Ann Rheum Dis. 2016;75(3):633–5.View ArticlePubMedGoogle Scholar
  5. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, Le Loët X, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933–8.View ArticlePubMedGoogle Scholar

Copyright

© The Author(s). 2018

Advertisement